Beckman Coulter’s NexGen Buy Is Latest Step In New MDx Platform Development | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
Adding to its molecular diagnostics development efforts, Beckman Coulter said last week that it has agreed to buy the remaining 80.1 percent of NexGen Diagnostics, a spin-out of Lumigen, that it did not already own.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.